Health Economics›Non-small cell lung cancer›All lines of therapy

All lines of therapy

Non-small cell lung cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Osimertinib monotherapy Variant #01	EGFR	R 155 554	28d	~16.6 mo	~38.1 mo	~2	~R 311 108 PFS proxy · indirect	15
Crizotinib monotherapy Variant #01	ALK	R 50 221	28d	~11.1 mo	—	~2	~R 100 441 PFS proxy · indirect	12
Ceritinib monotherapy Variant #01	ALK	R 35 198	28d	~11.0 mo	—	~2	~R 70 395 PFS proxy · indirect	2
Afatinib monotherapy Variant #01	EGFR	R 26 046	28d	~11.0 mo	~10.8 mo	~2	~R 52 091 PFS proxy · indirect	5
Cisplatin, Gefitinib, Pemetrexed Variant #01	EGFR	R 22 222	28d	—	~35.0 mo	~7	~R 155 111 PFS proxy · indirect	1
Gefitinib, Nedaplatin, Pemetrexed Variant #01 Partial	EGFR	R 21 781	28d	—	~35.0 mo	~7	~R 152 464 PFS proxy · indirect	1
Gefitinib monotherapy Variant #01	EGFR	R 4 278	28d	~9.7 mo	~17.0 mo	~2	~R 8 556 PFS proxy · indirect	27
Cisplatin and Vinorelbine (CVb) Variant #01	—	R 2 418	21d	—	~10.0 mo	~6	~R 14 510 PFS proxy · indirect	10
Dexamethasone monotherapy Variant #03	—	R 1 215	28d	—	—	~4	~R 4 861 indirect	—
Alectinib monotherapy Variant #01	ALK	R 108	28d	~27.0 mo	—	~2	~R 215 PFS proxy · indirect	7
Whole brain irradiation N/A - radiation	—	—	21d	—	—	—	—	1
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	~11.2 mo	—	~2	—	5
Teniposide monotherapy Variant #01 Partial	—	—	21d	—	—	~12	—	—
Teniposide and WBRT Variant #01 Partial	—	—	21d	—	—	~12	—	—
Dexamethasone and WBRT Variant #01	—	—	—	—	—	—	—	—

15 of 15 regimens shown